PMID: 9432334Jun 1, 1997Paper

The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients

Helicobacter
T TakimotoK Kimura

Abstract

The aim of this study was to evaluate the efficacy and tolerability of 1-week, low-dose triple therapy with lansoprazole, clarithromycin, and metronidazole (LCM) for the cure of H. pylori infection and to establish the adequate dosage of a new triple therapy for Japanese patients. One hundred four H. pylori-positive Japanese patients were assigned alternatively to one of two groups: one to receive either 30 mg lansoprazole once in the morning, 200 mg clarithromycin twice daily, and 250 mg metronidazole twice daily for 1 week (LCM1; n = 52); the other to receive 30 mg lansoprazole once in the morning, 200 mg clarithromycin twice daily, and 500 mg metronidazole twice daily for 1 week (LCM2; n = 52). H. pylori infection was assessed by smear, culture, and histological assessment (Giemsa stain) performed before and 4 weeks after cessation of the therapy. The overall cure rates of H. pylori infection were 92.3% (48 of 52; 95% confidence interval (CI), 85% to 100%) in LCM1 and 92.3% (48 of 52; 95% CI, 85% to 100%) in LCM2. The cure rates in the patients without prior treatment were 95.7% (44 of 46; 95% CI, 89%-100%) in LCM1 and 95.7% (45 of 47; 95% CI, 89%-100%) in LCM2. Minor side effects were observed in 7.7% of LCM1 and 9.6% of LC...Continue Reading

References

Mar 1, 1991·Journal of Gastroenterology and Hepatology·A T Axon
Jan 1, 1995·Journal of Clinical Gastroenterology·T TakimotoK Kimura
Jan 1, 1995·Journal of Clinical Gastroenterology·F Mégraud
Jan 1, 1995·Journal of Clinical Gastroenterology·H Lamouliatte
Jan 1, 1995·Journal of Clinical Gastroenterology·A T Axon
Jan 1, 1994·Scandinavian Journal of Infectious Diseases·L A NoachG N Tytgat
Jan 1, 1994·Scandinavian Journal of Gastroenterology. Supplement·A T Axon
Jan 1, 1996·Scandinavian Journal of Gastroenterology. Supplement·A T Axon, P Moayyedi

❮ Previous
Next ❯

Citations

Apr 6, 2004·Journal of Theoretical Biology·Ian M Joseph, Denise Kirschner
Nov 27, 1998·The American Journal of Medicine·D Peura
Oct 13, 1998·Alimentary Pharmacology & Therapeutics·G A PipkinJ R Wood
Aug 10, 2000·Alimentary Pharmacology & Therapeutics·K KihiraK Sugano
Nov 4, 2000·Journal of Gastroenterology and Hepatology·W H WangS K Lam
Jun 26, 2001·Journal of Gastroenterology and Hepatology·A NagaharaN Sato
May 21, 2003·Alimentary Pharmacology & Therapeutics·D Y GrahamH B El-Serag
Apr 2, 1999·Alimentary Pharmacology & Therapeutics·J Huang, R H Hunt

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.